Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Arrowhead Pharmaceuticals Inc ARWR

Healthcare Biotechnology
Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them. The Company's therapies, using a broad portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, trigger the RNA interference (RNAi) mechanism to induce rapid, deep and durable knockdown of target genes. The Company's Targeted RNAi Molecule (TRiMTM) platform... see more

Recent & Breaking News (NDAQ:ARWR)

Arrowhead to Present at Upcoming February Conferences

Press Releases February 16, 2016

Arrowhead Reports Fiscal 2016 First Quarter Results

Business Wire February 9, 2016

Arrowhead to Webcast Fiscal 2016 First Quarter Results

Business Wire February 2, 2016

Arrowhead's ARC-AAT Granted EMA Orphan Drug Designation

Business Wire January 19, 2016

Arrowhead Begins Dosing the Phase 2b MONARCH Combination Study of ARC-520 in Patients with Chronic Hepatitis B Infection

Business Wire January 7, 2016

Arrowhead Reports Fiscal 2015 Year End Results

Business Wire December 14, 2015

Arrowhead Added to NASDAQ Biotechnology Index®

Business Wire December 14, 2015

Today's Market Driven by Key Factors - Analyst Notes on Arrowhead Research, Omeros Corp, TriMas and Applied Micro Circuits

Accesswire December 11, 2015

Arrowhead Research Due Diligence Report: Tailwinds Ahead for this Researcher

Accesswire December 8, 2015

Arrowhead to Webcast Fiscal 2015 Year End Results

Business Wire December 7, 2015

Arrowhead's ARC-520 Leads to Consistent Immune Reactivation in Chimpanzees with Chronic Hepatitis B Infection

Business Wire December 7, 2015

Arrowhead Late-Breaking Clinical Data Shows that ARC-520 Can Produce Deep and Durable Reductions of Hepatitis B Viral Antigens and DNA

Business Wire November 16, 2015

Arrowhead Presents Data Showing Robust Sustained Anti-viral Effects with ARC-520 in Hepatitis B Infected Chimpanzees

Business Wire November 15, 2015

Arrowhead to Present at Upcoming Conferences

Business Wire November 11, 2015

Arrowhead Late-Breaker Abstract Accepted for Presentation at the AASLD Liver Meeting 2015

Business Wire October 20, 2015

Arrowhead Presents Overview of Its Broad RNAi Delivery Platform and Introduces New Subcutaneously Administered Format

Business Wire October 14, 2015

Arrowhead to Present at Upcoming Conferences

Business Wire October 5, 2015

Arrowhead Reports Peak Reduction in HBsAg of Up to 99% (1.9 log) After a Single Dose with Hepatitis B Candidate ARC-520 in Treatment Naïve Cohort of Phase 2a Study

Business Wire September 24, 2015

Arrowhead Nominates ARC-HIF2 As First RNAi Therapeutic Candidate Using Extrahepatic DPC(TM) Delivery System

Business Wire September 11, 2015

Arrowhead to Webcast Analyst Day Presentation on Hepatitis B Candidate ARC-520

Business Wire September 10, 2015